Clinical Trials Directory

Trials / Completed

CompletedNCT01507246

Adult Patients Undergoing Open Colectomy MA402S23B303

A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Pacira Pharmaceuticals, Inc · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is designed to compare the standard of care against EXPAREL(R) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Detailed description

This is a phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with EXPAREL compared with postsurgical administration of standardized intravenous (IV) morphine sulfate or sponsor-approved equivalent for postsurgical analgesia in adult patients undergoing open colectomy with general anesthesia.

Conditions

Interventions

TypeNameDescription
DRUGIV morphine sulfatePatients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
DRUGEXPAREL (bupivacaine liposome injectable suspension)Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care. All patients will be offered rescue analgesia, as needed.

Timeline

Start date
2011-12-01
Primary completion
2012-07-01
Completion
2012-08-01
First posted
2012-01-10
Last updated
2013-05-08
Results posted
2013-05-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01507246. Inclusion in this directory is not an endorsement.